• Alan Dal Pra, Fabio L Cury, and Luis Souhami.
• Division of Radiation Oncology, Department of Oncology, McGill University Health Centre, Montreal, Quebec, Canada.
• Int Braz J Urol. 2011 Mar 1; 37 (2): 161-75; discussion 176-9.

AbstractThe combined use of radiation therapy (RT) and androgen deprivation for patients with localized high-risk prostate cancer is commonly accepted as the standard treatment among uro-oncologists. Preclinical studies have provided rationale for the use of this combination. Additionally, results of phase 3 studies using conventional doses of RT have supported the combined approach. Other phase 3 studies have also shown a benefit for using higher doses of RT; however, the role of androgen deprivation in this context is not clear. The optimal duration of the androgen deprivation, in both the neoadjuvant and adjuvant setting, is still under investigation. This article critically reviews the data on the use of RT combined with androgen deprivation for the treatment of high-risk prostate cancer with emphasis on the results of phase 3 trials.

17 keywords...

hide…